Immunovaccine’s Respiratory Syncytial Virus vaccine moving to Phase 2 testing
The Safety Review Committee has approved DepoVax prophylactic Respiratory Syncytial Virus vaccine (DPX-RSV), developed by Immunovaccine Inc., for the next step in testing. Read More »